相似文献
1
Optimized relaxivity and stability of [Gd(H(2,2)-1,2-HOPO)(H2O)]- for use as an MRI contrast agent.
Inorg Chem. 2007 Jun 11;46(12):4796-8. doi: 10.1021/ic700399p. Epub 2007 May 11.
2
Gd-hydroxypyridinone (HOPO)-based high-relaxivity magnetic resonance imaging (MRI) contrast agents.
Acc Chem Res. 2009 Jul 21;42(7):938-47. doi: 10.1021/ar800250h.
3
GdIII complexes with fast water exchange and high thermodynamic stability: potential building blocks for high-relaxivity MRI contrast agents.
Chemistry. 2003 Aug 4;9(15):3555-66. doi: 10.1002/chem.200204612.
4
Substituent effects on Gd(III)-based MRI contrast agents: optimizing the stability and selectivity of the complex and the number of coordinated water molecules.
Inorg Chem. 2006 Oct 2;45(20):8355-64. doi: 10.1021/ic061262q.
5
1,2-hydroxypyridonates as contrast agents for magnetic resonance imaging: TREN-1,2-HOPO.
Inorg Chem. 2007 Oct 29;46(22):9182-91. doi: 10.1021/ic700985j. Epub 2007 Oct 3.
6
Toward optimized high-relaxivity MRI agents: thermodynamic selectivity of hydroxypyridonate/catecholate ligands.
Inorg Chem. 2004 Dec 27;43(26):8520-5. doi: 10.1021/ic0493447.
7
Bifunctional Gd(III) and Tb(III) chelates based on a pyridine-bis(iminodiacetate) platform, suitable optical probes and contrast agents for magnetic resonance imaging.
Contrast Media Mol Imaging. 2014 Jul-Aug;9(4):300-12. doi: 10.1002/cmmi.1576.
8
The effect of ligand scaffold size on the stability of tripodal hydroxypyridonate gadolinium complexes.
Inorg Chem. 2003 Apr 21;42(8):2577-83. doi: 10.1021/ic0261575.
9
Physico-Chemical Characterization of a Highly Rigid Gd(III) Complex Formed with a Phenanthroline Derivative Ligand.
Inorg Chem. 2022 Aug 29;61(34):13497-13509. doi: 10.1021/acs.inorgchem.2c02050. Epub 2022 Aug 16.
10
A highly stable gadolinium complex with a fast, associative mechanism of water exchange.
J Am Chem Soc. 2003 Nov 26;125(47):14274-5. doi: 10.1021/ja037441d.
引用本文的文献
1
High Antiproliferative Activity of Hydroxythiopyridones over Hydroxypyridones and Their Organoruthenium Complexes.
Biomedicines. 2021 Jan 27;9(2):123. doi: 10.3390/biomedicines9020123.
2
Gd@C metallofullerenes for neutron capture therapy-fullerene solubilization by poly(ethylene glycol)-block-poly(2-(, -diethylamino)ethyl methacrylate) and resultant efficacy .
Sci Technol Adv Mater. 2011 Jul 7;12(4):044607. doi: 10.1088/1468-6996/12/4/044607. eCollection 2011 Aug.
3
The importance of water exchange rates in the design of responsive agents for MRI.
Curr Opin Chem Biol. 2013 Apr;17(2):167-74. doi: 10.1016/j.cbpa.2012.12.012. Epub 2013 Jan 17.
4
Responsive MRI agents for sensing metabolism in vivo.
Acc Chem Res. 2009 Jul 21;42(7):948-57. doi: 10.1021/ar800237f.
5
Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents.
Contrast Media Mol Imaging. 2009 Mar-Apr;4(2):89-100. doi: 10.1002/cmmi.267.
6
Correlation of relaxivity with coordination number in six-, seven-, and eight-coordinate Mn(II) complexes of pendant-arm cyclen derivatives.
Inorg Chem. 2009 Jan 19;48(2):719-27. doi: 10.1021/ic8003068.
7
1,2-hydroxypyridonate/terephthalamide complexes of gadolinium(III): synthesis, stability, relaxivity, and water exchange properties.
Inorg Chem. 2009 Jan 5;48(1):277-86. doi: 10.1021/ic801730u.
本文引用的文献
1
An octadentate luminescent Eu(III) 1,2-HOPO chelate with potent aqueous stability.
Inorg Chem. 2007 Jul 9;46(14):5468-70. doi: 10.1021/ic700364t. Epub 2007 Jun 13.
2
Highly soluble tris-hydroxypyridonate Gd(III) complexes with increased hydration number, fast water exchange, slow electronic relaxation, and high relaxivity.
J Am Chem Soc. 2007 Feb 21;129(7):1870-1. doi: 10.1021/ja068026z. Epub 2007 Jan 30.
3
Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents.
Contrast Media Mol Imaging. 2006 May-Jun;1(3):128-37. doi: 10.1002/cmmi.100.
4
Substituent effects on Gd(III)-based MRI contrast agents: optimizing the stability and selectivity of the complex and the number of coordinated water molecules.
Inorg Chem. 2006 Oct 2;45(20):8355-64. doi: 10.1021/ic061262q.
5
"Cymothoe sangaris": an extremely stable and highly luminescent 1,2-hydroxypyridinonate chelate of Eu(III).
J Am Chem Soc. 2006 Aug 23;128(33):10648-9. doi: 10.1021/ja062597+.
6
Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.
Chem Soc Rev. 2006 Jun;35(6):512-23. doi: 10.1039/b510982p. Epub 2006 May 3.
7
Next generation, high relaxivity gadolinium MRI agents.
Bioconjug Chem. 2005 Jan-Feb;16(1):3-8. doi: 10.1021/bc049817y.
8
Gadolinium(III) 1,2-hydroxypyridonate-based complexes: toward MRI contrast agents of high relaxivity.
Inorg Chem. 2004 Sep 6;43(18):5492-4. doi: 10.1021/ic049028s.
9
Toward optimized high-relaxivity MRI agents: the effect of ligand basicity on the thermodynamic stability of hexadentate hydroxypyridonate/catecholate gadolinium(III) complexes.
Inorg Chem. 2003 Aug 11;42(16):4930-7. doi: 10.1021/ic026240s.
10
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications.
Chem Rev. 1999 Sep 8;99(9):2293-352. doi: 10.1021/cr980440x.
Zotero 插件